MeSH tree: D12.776.124.790.651.114.224.060
Drugs designed to target HER2-postive breast cancer could also benefit some patients with bile duct cancer, according to results of a patient trial to be presented on Thursday at the 36th EORTC-NCI-AACR Symposium on Molecular ...
Oct 23, 2024
0
31
For some proteins, a single mutation, or change in its DNA instructions, is all it takes to tip the balance between functioning normally and causing cancer. But despite causing major disease, these slightly mutated proteins ...
Oct 22, 2024
0
65
A treatment that rallies the immune system to destroy cancer raised the survival rate for advanced Hodgkin lymphoma patients to a remarkable 92%, suggesting a new standard therapy for the disease. The New England Journal ...
Oct 16, 2024
1
75
A study led by Dr. Hassan Aboul-Ella (Department of Microbiology, Faculty of Veterinary Medicine, Cairo University) has been published in the journal Molecular Biomedicine.
Oct 16, 2024
0
44
A top California health plan is set to offer one of the world's biggest-selling drugs for free in a bid to show the medicine can reach Americans affordably without going through the middlemen that typically control its flow.
Oct 7, 2024
0
22
Patient groups should be playing a central role in Canada's health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for ...
Oct 3, 2024
0
33
The 2023 cisplatin shortage led to a shift in utilization to alternative therapies for head and neck cancer (HNC), resulting in significant cost increases, according to a study presented at the American Society of Clinical ...
Oct 2, 2024
0
21
A Cleveland Clinic-led research collaboration between Timothy Chan, MD, Ph.D., Chair of Cleveland Clinic's Global Center for Immunotherapy, and Bristol Myers Squibb has published the most comprehensive overview to date of ...
Oct 1, 2024
0
71
The NRG Oncology NRG-HN005 phase II/III clinical trial has not met the non-inferiority criteria to proceed to the phase III portion of the study. The phase II portion of the NRG-HN005 evaluated two experimental treatment ...
Sep 30, 2024
0
25
Researchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal cancer to prevent long-term side effects halted a large, randomized Phase II/III trial after patients in the ...
Sep 30, 2024
0
24
